Market Place
Sourcing Support
SFA Therapeutics Strengthens IP In Autoimmune Disease And HCC
22 Oct 2024 //
PR NEWSWIRE
SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics
04 Sep 2024 //
PR NEWSWIRE
SFA Therapeutics Appoints New Chief Operating Officer
16 Jul 2024 //
PR NEWSWIRE
SFA Completes Enrollment For SFA-002 Psoriasis Phase 1b
30 May 2024 //
PR NEWSWIRE
SFA Strengthens Leadership With Chief Medical Officer Hire
02 May 2024 //
PR NEWSWIRE
SFA Therapeutics Announces Updated Psoriasis Data for SFA-002
09 Nov 2023 //
GLOBENEWSWIRE
SFA Therapeutics announces results for SFA-002 from Phase 1b clinical trial
14 Aug 2023 //
GLOBENEWSWIRE
SFA Announces FDA Clearance for Amendment to Extend Phase 1b Trial of SFA-002
11 Jan 2023 //
PR NEWSWIRE
Dr. Daniel Sauder joins the SFA Therapeutics Scientific Advisory Board
17 Oct 2022 //
EINNEWS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.